Exelixis | EXEL - Zysk Brutto





Zysk Brutto Zmiana Data
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Akebia Therapeutics USD -11.24M 12.39M 2025-12
Amgen USD 1.51B 2.41B 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
Bayer EUR -1.16B 735M 2025-09
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Cytokinetics USD -183.03M 123.15M 2025-12
Eisai JPY 22B 7.47B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Esperion Therapeutics USD 63.67M 95M 2025-12
Exelixis USD 252.69M 275K 2025-12
Genmab DKK 55M 427M 2025-12
Glaxosmithkline GBP 2.46B 569M 2025-09
Incyte USD 343.6M 46.34M 2026-03
Ionis Pharmaceuticals USD -93M 135M 2026-03
MacroGenics USD -14.93M 31.75M 2025-12
Merck USD 3.42B 3.32B 2025-12
Moderna USD -799M 612M 2025-12
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novartis USD 3.84B 802M 2026-03
Pfizer USD -1.64B 4.98B 2025-12
Puma Biotechnology USD 20.61M 24.76M 2024-09
Sanofi EUR -1.16B 6.23B 2025-12
Takeda JPY 133.86B 105.69B 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Xencor USD -4.27M 1.76M 2025-12